StockData
Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc. (ATXI) stock

ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/30
$0.43+0.00 (0.00%)

Close on Oct 16, 2026Market cap $1.42MP/E –Yield –

Avenue Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Avenue Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$1.38M. For fiscal 2025 it was -$1.83M. The highest annual figure on record is -$1.63M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.83M–
FY2024Dec 31, 2024-$9.03M–
FY2023Dec 31, 2023-$9.45M–
FY2022Dec 31, 2022-$7.60M–
FY2021Dec 31, 2021-$3.75M–
FY2020Dec 31, 2020-$4.61M–
FY2019Dec 31, 2019-$26.26M–
FY2018Dec 31, 2018-$18.22M–
FY2017Dec 31, 2017-$6.80M–
FY2016Dec 31, 2016-$1.63M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$475.00K–
Q1 FY2026Mar 31, 2026-$438.00K–
Q4 FY2025Dec 31, 2025-$854.00K–
Q3 FY2025Sep 30, 2025$383.00K–
Q2 FY2025Jun 30, 2025-$176.00K–
Q1 FY2025Mar 31, 2025-$1.19M–
Q4 FY2024Dec 31, 2024-$764.00K–
Q3 FY2024Sep 30, 2024-$2.89M–
Q2 FY2024Jun 30, 2024-$2.25M–
Q1 FY2024Mar 31, 2024-$3.12M–
Q4 FY2023Dec 31, 2023-$2.32M–
Q3 FY2023Sep 30, 2023-$889.00K–
Q2 FY2023Jun 30, 2023-$4.67M–
Q1 FY2023Mar 31, 2023-$1.57M–
Q4 FY2022Dec 31, 2022-$4.17M–
Q3 FY2022Sep 30, 2022-$554.00K–
Q2 FY2022Jun 30, 2022-$943.00K–
Q1 FY2022Mar 31, 2022-$1.93M–
Q4 FY2021Dec 31, 2021-$1.20M–
Q3 FY2021Sep 30, 2021-$536.00K–
Q2 FY2021Jun 30, 2021-$704.00K–
Q1 FY2021Mar 31, 2021-$1.31M–
Q4 FY2020Dec 31, 2020-$1.19M–
Q3 FY2020Sep 30, 2020-$932.00K–
Q2 FY2020Jun 30, 2020-$1.32M–
Q1 FY2020Mar 31, 2020-$1.17M–
Q4 FY2019Dec 31, 2019-$5.00M–
Q3 FY2019Sep 30, 2019-$1.71M–
Q2 FY2019Jun 30, 2019-$13.98M–
Q1 FY2019Mar 31, 2019-$5.57M–
Q4 FY2018Dec 31, 2018-$1.24M–
Q3 FY2018Sep 30, 2018-$4.14M–
Q2 FY2018Jun 30, 2018-$6.02M–
Q1 FY2018Mar 31, 2018-$6.82M–
Q4 FY2017Dec 31, 2017-$4.27M–
Q3 FY2017Sep 30, 2017-$1.88M–
Q4 FY2016Dec 31, 2016-$73.00K–
Q3 FY2016Sep 30, 2016-$443.00K–
Q2 FY2016Jun 30, 2016-$239.00K–

More Avenue Therapeutics figures

See a number that looks wrong?